1. Scrip

Finance Watch: Two New VC Funds Raise $955m To Back Life Science Companies

Illumina Ventures Brings In $325m; Jeito Garnered $630m

 
• By Mandy Jackson

Private Company Edition: Jeito says its new first fund is Europe’s largest life science-focused fund. Illumina will use its venture capital to support tools, diagnostics, therapeutics and more. Also, IASO closed a $108m series C round and Amolyt raised $80m in series C financing.

Finance Watch Private Company

As venture capital financings for biopharmaceutical companies continues to head into record-breaking territory again in 2021, Illumina Ventures and Jeito Capital announced two new venture capital funds that raised a combined $955m to back life science companies.

Newly disclosed VC funds during the past two weeks total well over $1bn, including a $375m fund announced by Lightstone Ventures on 14 September. Illumina Ventures said on 20 September that it closed a $325m fund, bringing its total capital under management to $560m

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Industry Makes Its Case To Trump In Effort To Sidestep Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a 232 investigation.

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.